Breaking News

Financial Report: AMRI 1Q08

...

Related CONTENT

05.05.08

AMRI

1Q Revenues: $53.6 million (+11%)

1Q Earnings: $4.7 million (+47%)

Comments: Total contract revenue increased to $45.3 million in the quarter (+10%). Discovery Services revenue was $13.3 million (+34%). Development and Small Scale Manufacturing revenue was $13.2 million (+29%). Large Scale Manufacturing revenue dropped to $18.7 million (-11%). Allegra royalties were $8.2 million (+15%).

Suggested For You

Partnering with a CDMO for Orphan Drug Development

Partnering with a CDMO for Orphan Drug Development

Curia to Expand U.S. Commercial Manufacturing Capability

Curia to Expand U.S. Commercial Manufacturing Capability

Generic APIs Portfolio

Generic APIs Portfolio

Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up

Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up

Vibalogics Advances Growth with Leadership Hires

Vibalogics Advances Growth with Leadership Hires

Curia to Acquire US-based LakePharma

Curia to Acquire US-based LakePharma

Curia to Acquire Integrity Bio

Curia to Acquire Integrity Bio

AMRI Becomes Curia

AMRI Becomes Curia

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

Gamma Biosciences Acquires Stake in Mirus Bio

Gamma Biosciences Acquires Stake in Mirus Bio

AMRI Adds R&D and Mfg. Solutions for Orphan Products

AMRI Adds R&D and Mfg. Solutions for Orphan Products

ProBioGen, Nobelpharma Enter Mfg. Agreement for Vax Project

ProBioGen, Nobelpharma Enter Mfg. Agreement for Vax Project

Tevogen Bio, BioCentriq Partner for COVID T-cell Therapy

Tevogen Bio, BioCentriq Partner for COVID T-cell Therapy

AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

Related Breaking News

Breaking News | Collaborations & Alliances

Rentschler Biopharma, XL-Protein Enter Manufacturing Pact

Will manufacture a long-acting, hyperactive recombinant human deoxyribonuclease I.
10.26.21
Collaborations & Alliances | Drug Development

Secarna, Denali Therapeutics Expand Strategic CNS Pact

To broaden use of Secarna's ASO discovery and development platform LNAplus and Denali's blood-brain barrier Transport Vehicle technology.
10.26.21
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News

BioNTech to Build mRNA Vaccine Mfg. Facility in Africa

The first mRNA manufacturing facility in Africa will enable an annual manufacturing capacity of several hundreds of million mRNA vaccine doses.
10.26.21
Collaborations & Alliances | Drug Delivery

Aptar Pharma Enters Exclusive Partnership with Stallergenes Greer

Will develop a novel digital health ecosystem for allergen immunotherapy treatment.
10.26.21
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News

Catalent Invests $230M in Harmans Gene Therapy Campus

Will house 18 CGMP viral vector manufacturing suites designed to accommodate multiple bioreactors up to 2,000-liter scale and commercial manufacturing.
10.26.21
Bio News | Biologics, Proteins, Vaccines | Facilities | Industry News

GTP Bioways Invests $14M in Biopharma Production Capabilities in France

Strengthens position as a CDMO in Europe by opening two new biopharmaceutical production units at Toulouse site.
10.25.21
Breaking News | Industry News | Promotions & Moves

Micropore Technologies Appoints Commercial Director

Denis Smit brings over 30 years of experience in the specialty chemicals industry.
10.25.21
Bio News | Breaking News | Collaborations & Alliances | Fill/Finish | Industry News | Parenterals

Sterile Fill/Finish CDMO swissfillon Joins ten23 health

ten23 health’s new combination of pharma development services with clinical & commercial fill/finish services will offer customers an end-to-end capabilities.
10.25.21
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News

Absci Opens Door to New Biotechnology Campus

Vancouver, WA headquarters expands company’s ability to accelerate discovery and development of next generation biologic drugs.
10.25.21
Breaking News | Facilities | Fill/Finish | Industry News | Injectables | Parenterals

Aenova Invests in Sterile Fill/Finish Area for Vials and Prefilled Syringes

The new sterile area at the Aenova site in Latina, Italy, goes into commercial production end of October 2021.
10.25.21
Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News

Exacis Biotherapeutics Partners with CCRM

Includes a cash investment into Exacis by CCRM Enterprises Holdings Ltd., which will be used to fund operations.
10.25.21
Breaking News | Industry News

Olon Brings Together Biocatalysis Experts

Creates new international network of scientific excellence for large-scale biocatalysis.
10.25.21
Breaking News | Drug Delivery | Facilities | Industry News

Renaissance Lakewood Marks Major Facility Expansion

Global CDMO invests more than $40 million in infrastructure, equipment and technology for 370,000 sq. ft. state-of-the-art Ocean County, NJ campus.
10.25.21
Breaking News | Collaborations & Alliances | Industry News | Information Technology

HistoWiz Closes $32 Million Series A Financing

The round was led by Vivo Capital and included other investors venBio, Asahi Kasei and Jon Oringer.
10.25.21
Breaking News | cGMP Manufacture | Clinical Trial Materials | Collaborations & Alliances | Fill/Finish | Industry News | Lyophilization

Alcami, PharmaTher Enter Manufacturing Agreement

U.S.-based CDMO to manufacture PharmaTher’s ketamine products for FDA Phase 3 clinical studies and global commercialization.
10.25.21